IMMUNITYBIO, INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised
IMMUNITYBIO, INC. (IBRX) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised of $0 for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions · last filed 2020-05-11
- IMMUNITYBIO, INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2019-12-31 was -$21.00K.
- IMMUNITYBIO, INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2019-06-30 was $0.00.
- IMMUNITYBIO, INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2018 was $57.00K, a 95.31% decline from fiscal 2017.
- IMMUNITYBIO, INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2017 was $1.22M.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 12 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 12 month as first filed |
|---|---|---|---|---|---|
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 | -$21.00K derived: sum of 2 quarters · filed 2020-05-11 | -$21.00K derived: sum of 3 quarters · filed 2020-05-11 | -$21.00K derived: sum of 4 quarters · filed 2020-05-11 | |
| 2019-12-31 | -$21.00K derived: 10-Q 12 month − 10-Q 9 month · filed 2020-05-11 | -$21.00K derived: sum of 2 quarters · filed 2020-05-11 | -$21.00K derived: sum of 3 quarters · filed 2020-05-11 | $39.20M 10-Q · filed 2020-05-11 | $39.22M 10-K · filed 2020-03-25 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $39.22M 10-Q · filed 2019-11-05 | $39.22M derived: sum of 4 quarters · filed 2020-05-11 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $39.22M 10-Q · filed 2019-08-06 | $39.22M derived: sum of 3 quarters · filed 2020-05-11 | $39.24M derived: sum of 4 quarters · filed 2020-05-11 | |
| 2019-03-31 | $39.22M 10-Q · filed 2020-05-11 | $39.22M derived: sum of 2 quarters · filed 2020-05-11 | $39.24M derived: sum of 3 quarters · filed 2020-05-11 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $22.00K derived: sum of 2 quarters · filed 2020-03-25 | $57.00K 10-K · filed 2020-03-25 | ||
| 2018-09-30 | $22.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $57.00K 10-Q · filed 2019-11-05 | |||
| 2018-06-30 | $35.00K 10-Q · filed 2019-08-06 | ||||
| 2017-12-31 | $1.22M 10-K · filed 2020-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |